February 25, 2021 – New York – Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it will report its financial results for the fourth quarter and full year ending December 31, 2020, on Thursday, March 4, 2021, after the close of the US market. The announcement will be followed by a conference call at 8:00 AM EST / 2:00 PM CET on Friday, March 5, 2021, prior to the open of the US market.

The live dial-in information for the conference call is:

US & Canada only: +1 (877) 407-3104

International: +1 (201) 493-6792

In addition, a replay of the call will be available until March 19th, by calling +1 877-660-6853 (Toll Free US & Canada); +1 201-612-7415 (Toll Free International).

Conference ID: 13716471